Merck & Co. (NYSE:MRK)‘s stock had its “hold” rating reissued by equities research analysts at Cowen in a report issued on Friday. They presently have a $67.00 price target on the stock. Cowen’s price target points to a potential upside of 13.89% from the company’s previous close.
A number of other analysts have also recently weighed in on the stock. Zacks Investment Research raised shares of Merck & Co. from a “hold” rating to a “buy” rating and set a $66.00 price objective on the stock in a report on Tuesday, April 17th. Bank of America raised their price objective on shares of Merck & Co. from $68.00 to $70.00 and gave the stock a “buy” rating in a report on Tuesday, April 17th. Morgan Stanley raised shares of Merck & Co. from an “equal weight” rating to an “overweight” rating and raised their price objective for the stock from $59.80 to $63.00 in a report on Tuesday, April 17th. BMO Capital Markets reissued a “buy” rating and set a $65.00 price objective on shares of Merck & Co. in a report on Monday, April 16th. Finally, Jefferies Group set a $56.00 price objective on shares of Merck & Co. and gave the stock a “hold” rating in a report on Friday, April 13th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and fifteen have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $66.67.
Shares of Merck & Co. stock opened at $58.83 on Friday. Merck & Co. has a 52-week low of $52.83 and a 52-week high of $66.41. The company has a quick ratio of 1.06, a current ratio of 1.33 and a debt-to-equity ratio of 0.62. The company has a market capitalization of $158,104.58, a P/E ratio of 14.78, a PEG ratio of 2.43 and a beta of 0.78.
Merck & Co. (NYSE:MRK) last issued its quarterly earnings results on Friday, February 2nd. The company reported $0.98 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.94 by $0.04. Merck & Co. had a net margin of 6.40% and a return on equity of 28.61%. The company had revenue of $10.43 billion during the quarter, compared to the consensus estimate of $10.48 billion. During the same quarter in the previous year, the firm earned $0.89 earnings per share. The firm’s quarterly revenue was up 3.1% on a year-over-year basis. equities research analysts anticipate that Merck & Co. will post 4.17 EPS for the current fiscal year.
In other news, insider Weir Mirian M. Graddick sold 24,000 shares of Merck & Co. stock in a transaction on Monday, April 16th. The shares were sold at an average price of $58.00, for a total value of $1,392,000.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Wendell P. Weeks sold 5,000 shares of Merck & Co. stock in a transaction on Friday, February 9th. The shares were sold at an average price of $53.57, for a total transaction of $267,850.00. Following the completion of the transaction, the director now directly owns 5,100 shares in the company, valued at $273,207. The disclosure for this sale can be found here. Insiders own 0.32% of the company’s stock.
Institutional investors have recently made changes to their positions in the company. Chemical Bank grew its position in Merck & Co. by 2.1% in the 4th quarter. Chemical Bank now owns 97,311 shares of the company’s stock valued at $5,476,000 after buying an additional 1,963 shares during the last quarter. Green Square Capital LLC grew its position in Merck & Co. by 17.0% in the 4th quarter. Green Square Capital LLC now owns 128,055 shares of the company’s stock valued at $7,273,000 after buying an additional 18,573 shares during the last quarter. Cambridge Investment Research Advisors Inc. grew its position in Merck & Co. by 10.6% in the 4th quarter. Cambridge Investment Research Advisors Inc. now owns 255,710 shares of the company’s stock valued at $14,389,000 after buying an additional 24,487 shares during the last quarter. Certified Advisory Corp purchased a new position in Merck & Co. in the 4th quarter valued at $184,000. Finally, Wagner Wealth Management LLC purchased a new position in Merck & Co. in the 4th quarter valued at $835,000. 74.60% of the stock is currently owned by institutional investors and hedge funds.
TRADEMARK VIOLATION NOTICE: “Cowen Reiterates Hold Rating for Merck & Co. (MRK)” was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece on another website, it was illegally stolen and reposted in violation of U.S. & international copyright legislation. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2018/04/22/cowen-reiterates-hold-rating-for-merck-co-mrk.html.
Merck & Co. Company Profile
Merck & Co, Inc provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular diseases, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases.
Receive News & Ratings for Merck & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. and related companies with MarketBeat.com's FREE daily email newsletter.